Key Takeaways
- Shares of HIMS climbed approximately 13% on April 16, 2026, driven by FDA announcement regarding peptide regulatory evaluations
- FDA confirmed advisory committee sessions for July 23-24 to assess multiple peptides for potential 503A Bulks List addition
- BofA Securities increased price target from $21 to $25 while retaining Neutral stance
- Analysts view this development as a long-term positive with minimal immediate earnings impact
- Company insiders have offloaded roughly $3.4 million in shares over three months without any buying activity
Shares of Hims & Hers Health (HIMS) experienced a substantial rally, jumping as much as 13.72% on April 16, 2026, following an FDA announcement regarding planned advisory sessions to review multiple wellness peptides currently limited under existing regulatory guidelines.
Hims & Hers Health, Inc., HIMS
The regulatory agency released a formal notice establishing Pharmacy Compounding Advisory Committee sessions set for July 23 and 24. These gatherings will focus on examining various peptide-based bulk drug substances for potential placement on the 503A Bulks List. It’s important to recognize this represents a preliminary procedural action rather than final approval.
Public statements from RFK Jr. regarding prospective FDA regulatory modifications further energized investor sentiment. The agency is considering removing restrictions on as many as 12 peptides, with evaluation timelines extending into February 2027.
The stock had demonstrated momentum prior to this announcement. Throughout the preceding week, HIMS gained approximately 25%, based on InvestingPro metrics.
Bank of America Elevates Valuation Target
BofA Securities adjusted its outlook by raising the HIMS price target from $21 to $25, though the firm maintained its Neutral recommendation. The adjustment involved increasing the target valuation multiple to roughly 25.5 times from 21.5 times, reflecting elevated peer valuations and peptide potential.
Analysts at BofA highlighted how this development might enable the company to redirect current GLP-1 compounding infrastructure toward alternative peptides. This consideration holds significance since HIMS has committed capital to GLP-1 operations following previous FDA compounding limitations.
The firm adopted a measured perspective on the news. Analysts characterized it as “an initial small step” and indicated no anticipated near-term influence on earnings projections absent a definitive FDA determination.
The FDA additionally noted that the majority of substances under consideration continue to present potential safety concerns according to existing guidance.
Recent HIMS Developments
The company recently integrated Novo Nordisk’s FDA-cleared GLP-1 treatments into its service offering, featuring Wegovy in both injectable and oral formulations. The Wegovy tablet represents the sole FDA-authorized GLP-1 weight management pill presently on the market.
Additionally, the platform will provide Ozempic injection pens, though regulatory approval limits these to Type 2 diabetes treatment.
The GLP-1 marketplace has grown increasingly competitive. Amazon Pharmacy launched same-day delivery for Eli Lilly’s recently approved GLP-1 medication Foundayo, creating additional challenges for both Novo Nordisk and HIMS.
Regarding insider transactions, CFO Oluyemi Okupe submitted filings to divest stock worth approximately $4.9 million. During the previous three-month period, company insiders collectively sold roughly $3.4 million in shares, with zero acquisition transactions reported.
HIMS currently maintains a P/E ratio ranging between 45-47x. InvestingPro’s evaluation indicates the stock appears overvalued compared to Fair Value calculations. The enterprise maintains a market capitalization of approximately $5.54 billion alongside a subscriber base exceeding 2 million.
BofA’s 2026 EBITDA projection stands roughly 21% beneath Wall Street consensus estimates, a discrepancy the firm has previously documented in research notes.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
